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1. Introduction
This report concerns problematic issues in the diagnosis and 
management of allergic rhinitis (AR) in South Africa, as reviewed 
by the South African Allergic Rhinitis Working Group (SAARWG) 
in February 2012. 
2. AR in infants
Practical paediatric experience suggests that AR in infants, first 
reported in 1961,1 is not uncommon. However, its prevalence is 
unknown and complicated by inconclusive studies suggesting that 
‘seasonal AR’ is uncommon in the first 2 years of life.2
The 2003 prospective study on the influence of perinatal factors on 
the occurrence of asthma and allergies (PIPO) in Belgium surveyed 
1 300 infants from the general population.3 In the first phase of the 
study, 260 infants were monitored to the age of 1 year and subjected 
to a questionnaire, clinical examination and allergy testing. At the 
end of the first phase, 44% of the infants were reported to have 
snoring and noisy breathing, while positive allergy test results were 
reported in 21%. While this does not prove the existence of AR in 
infancy, it suggests that this diagnosis is probable in some infants.
The following symptoms should be sought where AR is considered 
in infants: noisy breathing, snuffles, snorting; snoring; sneezing; 
feeding difficulty; failure to thrive; irritability, disturbed sleep; watery 
nasal discharge; nose-rubbing on pillow/bedding/mother; recurrent 
serous otitis media; and cough/wheeze.
Features on examination that suggest AR in infants include: facial 
appearance (allergic facies); pallor; Dennie-Morgan lines; mouth-
breathing; tongue thrusting; a pale, wet and swollen nasal mucosa; 
serous otitis media; and atopic dermatitis (often present).
Skin-prick tests are useful for identifying allergens, even in very 
young children, and they require only a limited panel. The most 
common allergens originate from foods (especially milk, peanut and 
wheat) and inhalants (especially house dust mite, cats and dogs).
There is no published literature on the manner in which to treat 
AR in infants. However, 3 aspects of treatment deserve mention: 
(i) The avoidance of identified allergens and irritants (especially 
passive environmental tobacco smoke) is critical. Parents must 
also be advised to avoid unnecessary and potentially harmful 
therapies, including most over-the-counter (OTC) cough and 
cold medications and topical decongestants. 
(ii) The use of saline nasal preparations should strongly be 
recommended. 
(iii) All forms of therapy for older children (including antihistamines, 
topical corticosteroids and montelukast) are not registered for 
use in infants. While their use is often necessary, clinicians must 
be careful to balance efficacy with safety.
3. Laboratory-based allergy surveillance 
in private practice (2007 - 2011)
Allergy data from South Africa and Africa are limited, with infrequent 
updates on circulating aero-allergens and the possible impact of 
climate change. Existing studies are not generalisable, have small 
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sample sizes and assess specific populations. Therefore, alternative 
ways to audit allergy data have been suggested, including laboratory 
surveillance of allergy test requests and identified allergens.4 
To assess the usefulness of laboratory-based allergy surveillance, 
all allergy test requests and results from 1 September 2007 to 31 
August 2011 were extracted from Lancet Laboratories (South Africa 
and Africa). Test results including total immunoglobulin E (IgE), 
ImmunoCAP, Immuno solid-phase allergen chip (ISAC), eosinophil 
cationic protein (ECP) and skin-prick tests were analysed, and data 
on trends (seasonal), location (country, province and district), doctor 
type and patient profile (age and sex) were collected.
In total, 1 150 493 allergy-related tests were requested 
(Table 1), including 129 848 requests for total IgE. Although 
clinical information was not available, it is assumed that total IgE 
requests were used primarily as part of an allergy work-up. Most 
published allergy testing guidelines from South Africa and the rest 
of the world discourage the use of total IgE as a screening test for 
allergy.5,6 The SAARWG stresses the importance of an adequate 
history in uncovering likely allergens as a source of AR. 
The 2011 total paediatric allergy testing expenditure of the large 
healthcare funder, Discovery Health, approximated R10 million. 
ImmunoCAP testing contributed to 66% of the expenditure, while 11.2% 
was spent on total IgE testing in children aged ≤16 years (Discovery 
Health, 2010). Directed testing according to established algorithms with 
appropriate screening and follow-up tests must be emphasised in practice. 
4. Diagnosis of AR and sinusitis
AR is an inflammatory condition of the lining of the nose, 
characterised by nasal symptoms, including anterior or posterior 
rhinorrhoea, sneezing, nasal blockage and/or itching of the nose, 
often associated with ocular symptoms.7 Itch, sneeze and profuse 
rhinorrhoea are classic of early AR. However, nasal obstruction 
manifests as a prominent symptom with time.8 Ocular symptoms 
present with itchy, red and watery eyes.9
The diagnosis of sinusitis is guided by a recent European position 
paper on rhinosinusitis and nasal polyps (EPOS).10 The document 
makes the case that acute rhinosinusitis is often viral and related to 
an upper respiratory tract infection (URTI) (Table 2). Acute bacterial 
sinusitis may be considered when symptoms persist for longer than 
10 days. The diagnosis of chronic sinusitis is warranted by symptoms 
persisting for longer than 12 weeks.
5. AR and sinusitis treatment principles
Intranasal corticosteroids (INS) are the gold-standard first-line 
therapy for moderate/severe and/or persistent AR.10 Several studies 
found INS to be more effective than anti-histamines (AH) against 
nasal symptoms.7,11,12 INS treatment may optimise the control of 
co-morbidities such as asthma, sinusitis, conjunctivitis and otitis 
media.13,14
Acute bacterial sinusitis (ABS) is most often preceded by a viral 
URTI. Other factors that may lead to inflammation of the nose and 
paranasal sinuses and predispose to ABS include allergy, trauma 
and dental infection. Outcomes deemed necessary for managing 
ABS include eradication of bacterial pathogens from the site of 
infection, returning the sinuses to health, decreasing the duration 
of symptoms, preventing severe complications and decreasing the 
likelihood of chronic disease. There is mounting evidence that topical 
INS treatment is beneficial in managing ABS.15,16
Table 1. Allergy-related tests conducted by Lancet Laboratories, South Africa and Africa (2007 - 2011)
Test
Number of tests performed (n)
1 September 2007 - 
31 August 2008
1 September 2008 - 
31 August 2009
1 September 2009 - 
31 August 2010
1 September 2010 - 
31 August 2011
Total 
(1 September 2007 - 
31 August 2011)
IgE 30 199 32 488 33 520 33 641 129 848
ECP 363 324 314 132 1 133
ImmunoCAP 201 941 244 597 258 104 250 109 954 751
ISAC N/A N/A 309 1 854 2 163
Skin-prick test 14 442 15 902 16 255 15 999 62 598
Total (N) 246 945 293 311 308 502 301 735 1 150 493
N/A = not available; ECP = eosinophil cationic protein; ISAC = Immuno solid-phase allergen chip.
Table 2. Diagnosis of acute and chronic sinusitis
Acute bacterial sinusitis (ABS)
Chronic rhinosinusitis without nasal polyps 
(CRSsNP)
Chronic rhinosinusitis with nasal polyps 
(CRSwNP)
Anterior or post-nasal discharge Anterior or post-nasal discharge Anterior or post-nasal discharge  
OR OR OR
Nasal obstruction
± Facial pain/pressure
± Change in sense of smell
Nasal obstruction
± Facial pain/pressure
± Change in sense of smell
Nasal obstruction
± Facial pain/pressure
± Change in sense of smell
•	Lasts >10 days and <3 months*
•	Severe lasting purulence or temperature
•	Worsening in <10 days
>12 weeks and no nasal polyps >12 weeks and documented nasal polyps
*Acute URTI lasting <10 days, no lasting purulence, no worsening, no severe temperature = ‘acute viral sinusitis’ or ‘a cold’.
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Fig. 1. Algorithm for the diagnosis and management of rhinitis.
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6. Evidence for the value of OTC 
cough and cold medicines
OTC cough and cold medicines are frequently used by patients 
and often prescribed by doctors. Evidence is absent or negative 
for efficacy for many of these preparations. Cough mixtures have 
no proven value in adults or children in upper (URT) and lower 
respiratory tract (LRT) pathologies.17 Mucolytic agents have been 
studied and a meta-analysis of 3 studies reveals that they have some 
benefit in URTIs.18 Oral decongestants and antihistamines have not 
demonstrated efficacy in most clinical conditions.19,20
The lack of efficacy and unfavourable safety profile of many agents 
is a major concern. The use of most agents in young children has 
recently been restricted in the USA.21 However, even legal restriction 
has not shown changed prescription or usage patterns in many 
countries.22
Topical decongestants improve the major symptoms of nasal 
congestion in AR. However, their use may produce rhinitis 
medicamentosa, which may occur as early as day 3 in some patients. 
Their use should therefore be restricted to no more than 7 - 10 days.23 
7. The ‘united airway’ concept – 
renewed interest
Despite discussion by world experts on the link between AR and 
asthma, the SAARWG believes that the evidence strongly supports 
the concept of a ‘united airway’ and that the identification and 
management of both conditions (AR and asthma) improves symptoms 
and quality of life, reduces severity of disease and is cost-saving.24-28
The reasoning for a link between AR and asthma centres on the 
systemic nature of inflammation in these conditions operating on a 
common epithelium in both sites.29 
8. Immunotherapy
Patients with persistent AR, affecting quality of life and resistant to 
maximal therapy, should be assessed for sensitisation. Patients who 
are monosensitive or ‘clinically monosensitive’ (i.e. sensitised to more 
than one allergen but with a clear pattern demonstrating one allergen 
as the important one) should be offered immunotherapy.30
9. Algorithm for the diagnosis and 
management of rhinitis
An algorithm proposed by the SAARWG for the diagnosis and 
management of rhinitis in South Africa is presented Fig. 1. 
10. Conclusion
AR is common, important and troubling to patients; therefore, every 
effort should be made to target therapy correctly. Patient education is 
important in the management of AR.
SAARWG members: G Carter, G Des Marais, C Els, C Gravett, I Hunt, 
M Ossip, O F Jooma, A Manjra, L Maron, A Mc Cullogh, M McDonald, 
P C Potter, R Seedat, and L Woolf.
Endorsements. This Guideline is endorsed by the Allergy Society of South 
Africa.
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